DOCSLIB.ORG

1570 Cough Suppressants Expectorants Mucolytics and Nasal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1570 Cough Suppressants Expectorants Mucolytics and Nasal 1570 Cough Suppressants Expectorants Mucolytics and Nasal Decongestants of a link between UK products containing phenylpropanolamine 90% of a dose is excreted unchanged in the urine with- Interactions and haemorrhagic stroke was weak (phenylpropanolamine is not in 24 hours. The half-life has been reported to be about Use of pholcodine with alcohol or other CNS depres- licensed as an appetite suppressant in the UK and the maximum recommended dose of 100 mg daily was lower than the 150 mg 3 to 5 hours. sants may increase the effects on the CNS. daily recommended in the USA). It was therefore suggested by ◊ References. UK commentators that use of licensed doses, with appropriate Uses and Administration 2 1. Simons FER, et al. Pharmacokinetics of the orally administered precautions, posed no additional risk. However, subsequently, decongestants pseudoephedrine and phenylpropanolamine in Pholcodine is a centrally acting cough suppressant that UK preparations containing phenylpropanolamine have either children. J Pediatr 1996; 129: 729–34. has actions and uses similar to those of dextromethor- been reformulated (mainly with pseudoephedrine) or withdrawn 2. Chester N, et al. Elimination of ephedrines in urine following by the manufacturers. multiple dosing: the consequences for athletes, in relation to phan (p.1556). It is given orally in a usual dose of 5 to doping control. Br J Clin Pharmacol 2004; 57: 62–7. 1. Lake CR, et al. Adverse drug effects attributed to phenylpropa- 10 mg three or four times daily. For children’s doses, nolamine: a review of 142 case reports. Am J Med 1990; 89: see Administration in Children, below. The citrate has 195–208. Uses and Administration also been used. Pholcodine polistirex (a pholcodine 2. Moffatt T, et al. Phenylpropanolamine: putting the record Phenylpropanolamine is a mainly indirect-acting sym- and sulfonated diethenylbenzene-ethenylbenzene co- straight. Pharm J 2000; 265: 817. pathomimetic (p.1408) with an action similar to that of 3. Kernan WN, et al. Phenylpropanolamine and the risk of hemor- polymer complex) has been used in modified-release rhagic stroke. N Engl J Med 2000; 343: 1826–32. ephedrine (p.1559) but less active as a CNS stimulant. preparations. 4. Ernst ME, Hartz A. Phenylpropanolamine and hemorrhagic Phenylpropanolamine has been given orally as the hy- stroke. N Engl J Med 2001; 344: 1094. Administration in children. Although pholcodine is licensed drochloride for the symptomatic treatment of nasal for use in children, over-the-counter cough and cold preparations 5. Wolowich WR, et al. Phenylpropanolamine and hemorrhagic stroke. N Engl J Med 2001; 344: 1094–5. congestion (p.1548). It has frequently been used in containing cough suppressants (including pholcodine) should be used with caution and generally avoided in those under 2 years 6. Stier BG, Hennekens CH. Phenylpropanolamine and hemorrhag- combination preparations for the relief of cough and ic stroke in the Hemorrhagic Stroke Project: a reappraisal in the cold symptoms. of age (see p.1547). The following oral doses of pholcodine are context of science, the Food and Drug Administration, and the given in the BNFC for use in children: law. Ann Epidemiol 2006; 16: 49–52. In the management of nasal congestion, phenylpropa- • 2 to 5 years: 2 mg three times daily 7. Committee on Safety of Medicines/Medicines Control Agency. nolamine hydrochloride has been given in oral doses of • 5 to 12 years: 2 to 5 mg three or four times daily Phenylpropanolamine and haemorrhagic stroke. Current Prob- up to 50 mg twice daily as modified-release prepara- lems 2001; 27: 5–6. Also available at: http://www.mhra.gov.uk/ home/idcplg?IdcService=GET_FILE&dDocName= tions. Preparations CON007458&RevisionSelectionMethod=LatestReleased (ac- BP 2008: Pholcodine Linctus; Strong Pholcodine Linctus. cessed 04/01/07) Other uses of phenylpropanolamine have included the control of urinary incontinence in some patients (see Proprietary Preparations (details are given in Part 3) p.2180). It has also been given in the management of Austral.: Actifed CC Dry; Actuss†; Duro-Tuss; Logicin Cough Suppres- Interactions sant†; Nyal Plus+ Dry Cough†; Ordov Dry Tickly Cough†; Pholtrate†; As for Sympathomimetics, p.1407. For a comment that some forms of priapism (see under Metaraminol, Tussinol; Cz.: Neocodin†; Fin.: Tuxi; Fr.: Biocalyptol; Broncorinol toux p.1333). Phenylpropanolamine has been used to sup- seche†; Codotussyl Toux Seche; Dimetane; Humex; Pharmakod toux drug interactions were likely to have been involved in seche; Respilene; Rhinathiol Toux Seche Pholcodine; Sirop des Vosges Toux many adverse events associated with phenylpropa- press appetite in the management of obesity (p.2149) Seche; Hong Kong: Duro-Tuss; Uni-Pholco; Irl.: Expulin Dry Cough; Phol- but the use of stimulants is no longer recommended. codex; Pholcolin; Malaysia: Dhacodine; Duro-Tuss; Norw.: Tuxi; NZ: Ac- nolamine see under Adverse Effects and Precautions, tifed CC Dry†; Duro-Tuss; S.Afr.: Pholcolinct; Pholtex; Singapore: Duro- above. Due to its indirect action, hypertensive crisis is Phenylpropanolamine polistirex (a phenylpropa- Tuss; Spain: Trophires†; UK: Benylin Childrens Dry Coughs; Boots Dry Cough Syrup 1 Year Plus; Galenphol; Hill’s Balsam Dry Cough; Pavacol-D; a particular risk in patients receiving MAOIs. nolamine and sulfonated diethenylbenzene-ethenyl- Tixylix Daytime. benzene copolymer complex) has also been used, as Amantadine. Severe psychosis has been reported1 in a woman Multi-ingredient: Austral.: Chemists Own Kiddicol; Demazin Cough & taking amantadine with phenylpropanolamine. In another re- have phenylpropanolamine bitartrate, phenylpropa- Cold; Difflam Anti-inflammatory Lozenges with Cough Suppressant; Duro- 2 Tuss Cough Lozenges; Duro-Tuss Decongestant; Duro-Tuss Dry Cough port, a 39-year-old man had intense and recurrent déjà vu expe- nolamine maleate, and phenylpropanolamine sulfate. Plus Nasal Decongestant; Duro-Tuss Expectorant; Phensedyl†; Tixylix Nigh- riences after taking amantadine with phenylpropanolamine for Preparations time; Belg.: Broncho-pectoralis Pholcodine; Eucalyptine Pholcodine; Euca- viral influenza. The effect ceased when he stopped both drugs. lyptine Pholcodine Le Brun†; Folex†; Norhitis; Pectorhinyl; Pholco-Mere- The authors suggested that his symptoms were due to increased USP 31: Chlorpheniramine Maleate and Phenylpropanolamine Hydrochlo- prine; Cz.: Biocalyptol S†; Fr.: Atouxx; Broncalene; Clarix; Denoral†; ride Extended-release Capsules; Chlorpheniramine Maleate and Phenyl- Hexapneumine; Isomyrtine†; Polery; Trophires; Hong Kong: Biocalyptol†; dopamine activity caused by the combination. propanolamine Hydrochloride Extended-release Tablets; Phenylpropa- Duro-Tuss Decongestant; Duro-Tuss Expectorant; Hexapneumine; Tripe P; 1. Stroe AE, et al. Psychotic episode related to phenylpropa- nolamine Hydrochloride Capsules; Phenylpropanolamine Hydrochloride India: Tixylix; Irl.: Day Nurse; Expulin; Expulin Childrens Cough; Malay- nolamine and amantadine in a healthy female. Gen Hosp Psychi- Extended-release Capsules; Phenylpropanolamine Hydrochloride Extend- sia: Difflam Anti-Inflammatory Lozenges (with cough suppressant); Duro- atry 1995; 17: 457–8. ed-release Tablets; Phenylpropanolamine Hydrochloride Oral Solution; Tuss Expectorant; Phensedyl Dry Cough; Promedyl Plus; Rhynacol; Russedyl Phenylpropanolamine Hydrochloride Tablets. Plus; Tixylix†; NZ: Difflam Cough; Duro-Tuss Cough; Duro-Tuss Expecto- 2. Taiminen T, Jääskeläinen SK. Intense and recurrent déjà vu ex- rant; Duro-Tuss Lozenges; Phensedyl Dry Family Cough†; Tixylix; S.Afr.: periences related to amantadine and phenylpropanolamine in a Proprietary Preparations (details are given in Part 3) Contra-Coff; Docsed; Folcofen; Pholtex Linctus; Procof; Respinol Com- healthy male. J Clin Neurosci 2001; 8: 460–2. Fin.: Rinexin; Ger.: Boxogetten S; Recatol mono; Norw.: Rinexin; Philipp.: pound; Tixylix; Singapore: 3P†; Duro-Tuss Cough Lozenges; Duro-Tuss Decolgen; Desotap; Disudrin; Naldec; Nasadec; Nasaphen; Nasathera P; Decongestant; Duro-Tuss Expectorant; Spain: Caltoson Balsamico; Switz.: Antipsychotics. A 27-year-old woman with schizophrenia and Neo-Coldan; S.Afr.: Restaslim†; Swed.: Rinexin; Switz.: Kontexin†; Pecto-Baby; Phol-Tussil; Phol-Tux; Tussiplex†; UK: Boots Nightime Cough T-wave abnormality of the heart, who had responded to thiori- Merex†; Slim Caps. Syrup 1 Year Plus; Cough Nurse; Day & Night Nurse; Day Nurse; Expulin dazine 100 mg daily with procyclidine 2.5 mg twice daily, died Multi-ingredient: numerous preparations are listed in Part 3. Childrens Cough†; Nirolex Day Cold & Flu; Nirolex Night Cold & Flu; Tix- from ventricular fibrillation within 2 hours of taking a single ylix Cough & Cold; Tixylix Night-Time. dose of a preparation reported to contain chlorphenamine maleate 4 mg with phenylpropanolamine hydrochloride 50 mg (Contac C), concurrently with thioridazine.1 Pholcodine (BAN, rINN) Pipazetate (BAN, rINN) 1. Chouinard G, et al. Death attributed to ventricular arrhythmia in- duced by thioridazine in combination with a single Contac C Folcodina; Folkodiini; Folkodin; Folkodin monohydrát; Folkodinas; D-254; Pipazétate; Pipazetato; Pipazetatum; Pipazethate (USAN); capsule. Can Med Assoc J 1978; 119: 729–31. Pholcodinum; Pholcodinum Monohydricum. 3-O-(2-Morpholi- SKF-70230-A; SQ-15874. 2-(2-Piperidinoethoxy)ethyl pyri- noethyl)morphine monohydrate. do[3,2-b][1,4]benzothiazine-10-carboxylate. Antivirals. A patient taking an over-the-counter nasal decon- gestant preparation
Load more

Recommended publications
  • BUREAU CIRCULAR No. 12 S. 1997
    REPUBLIC OF THE PHILIPPINES DEPARTMENT OF HEALTH BUREAU OF FOOD AND DRUGS D.O.H. Compound Alabang, Muntinlupa Metro Manila September 4, 1997 BUREAU CIRCULAR No. 12 series 1997 TO : ALL COSMETIC MANUFACTURERS, TRADERS, IMPORTERS AND PARTIES CONCERNED SUBJECT : 1997 UPDATED LISTING OF COSMETIC INGREDIENTS The BFAD Management Committee, in its meeting on August 28, 1997 has adopted and approved the updated technical standards and requirements set for cosmetic ingredients as recommended by the Joint BFAD and Cosmetic Industry Study Group’s Technical Committee. As such, the sections of Bureau Circular No. 19-A series of 1997 hereunder described are amended by the listings of cosmetic ingredients hereunto appended, to wit: Section III - Restricted Ingredients For Use In Cosmetics Table I : List Of Substances Which Cosmetics Products Must Not Contain Except Subject To The Restrictions And Conditions Specified Table II : List Of Preservatives Which Cosmetic Products May Contain Subject To The Restrictions And Conditions Specified Table III : List Of Preservatives Provisionally Allowed Section IV - Non-Permissible Colors In Cosmetics Table IV : Non-Permissible Colors In Cosmetics Section V - Permissible Color Additives Table V : Permissible Color Additives; List Of Colorants Restricted/Allowed For Cosmetic Products Table VI : List Of Provisionally Allowed Colors In Cosmetic Preparations Section VI: Sunscreen Agents Table VII : List Of Sunscreen Agents Which Cosmetics Products May Contain Table VIII : List Of Sunscreen Agents Which Cosmetics Products May Provisionally Contain Table IX : List Of Substances Which Must Not Form Part Of The Composition Of Cosmetic Products Additionally, BFAD has decided to extend the approval of products containing benzethonium chloride only up to December 31, 1997 in view of the ban of the said ingredient under the European Economic Community’s (EEC) August 1996 Directive, unless additional safety data on the same are found before December 31, 1997.
    [Show full text]
  • Pdf; Chi 2015 DPP Air in Cars.Pdf; Dodson 2014 DPP Dust CA.Pdf; Kasper-Sonnenberg 2014 Phth Metabolites.Pdf; EU Cosmetics Regs 2009.Pdf
    Bouge, Cathy (ECY) From: Nancy Uding <[email protected]> Sent: Friday, January 13, 2017 10:24 AM To: Steward, Kara (ECY) Cc: Erika Schreder Subject: Comments re. 2016 CSPA Rule Update - DPP Attachments: DPP 131-18-0 exposure.pdf; Chi 2015 DPP air in cars.pdf; Dodson 2014 DPP dust CA.pdf; Kasper-Sonnenberg 2014 phth metabolites.pdf; EU Cosmetics Regs 2009.pdf Please accept these comments from Toxic-Free Future concerning the exposure potential of DPP for consideration during the 2016 CSPA Rule update. Regards, Nancy Uding -- Nancy Uding Grants & Research Specialist Toxic-Free Future 206-632-1545 ext.123 http://toxicfreefuture.org 1 JES-00888; No of Pages 9 JOURNAL OF ENVIRONMENTAL SCIENCES XX (2016) XXX– XXX Available online at www.sciencedirect.com ScienceDirect www.elsevier.com/locate/jes Determination of 15 phthalate esters in air by gas-phase and particle-phase simultaneous sampling Chenchen Chi1, Meng Xia1, Chen Zhou1, Xueqing Wang1,2, Mili Weng1,3, Xueyou Shen1,4,⁎ 1. College of Environmental & Resource Sciences, Zhejiang University, Hangzhou 310058, China 2. Zhejiang National Radiation Environmental Technology Co., Ltd., Hangzhou 310011, China 3. School of Environmental and Resource Sciences, Zhejiang Agriculture and Forestry University, Hangzhou 310058, China 4. Zhejiang Provincial Key Laboratory of Organic Pollution Process and Control, Hangzhou 310058, China ARTICLE INFO ABSTRACT Article history: Based on previous research, the sampling and analysis methods for phthalate esters (PAEs) Received 24 December 2015 were improved by increasing the sampling flow of indoor air from 1 to 4 L/min, shortening the Revised 14 January 2016 sampling duration from 8 to 2 hr.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • General Pharmacology
    GENERAL PHARMACOLOGY Winners of “Nobel” prize for their contribution to pharmacology Year Name Contribution 1923 Frederick Banting Discovery of insulin John McLeod 1939 Gerhard Domagk Discovery of antibacterial effects of prontosil 1945 Sir Alexander Fleming Discovery of penicillin & its purification Ernst Boris Chain Sir Howard Walter Florey 1952 Selman Abraham Waksman Discovery of streptomycin 1982 Sir John R.Vane Discovery of prostaglandins 1999 Alfred G.Gilman Discovery of G proteins & their role in signal transduction in cells Martin Rodbell 1999 Arvid Carlson Discovery that dopamine is neurotransmitter in the brain whose depletion leads to symptoms of Parkinson’s disease Drug nomenclature: i. Chemical name ii. Non-proprietary name iii. Proprietary (Brand) name Source of drugs: Natural – plant /animal derivatives Synthetic/semisynthetic Plant Part Drug obtained Pilocarpus microphyllus Leaflets Pilocarpine Atropa belladonna Atropine Datura stramonium Physostigma venenosum dried, ripe seed Physostigmine Ephedra vulgaris Ephedrine Digitalis lanata Digoxin Strychnos toxifera Curare group of drugs Chondrodendron tomentosum Cannabis indica (Marijuana) Various parts are used ∆9Tetrahydrocannabinol (THC) Bhang - the dried leaves Ganja - the dried female inflorescence Charas- is the dried resinous extract from the flowering tops & leaves Papaver somniferum, P album Poppy seed pod/ Capsule Natural opiates such as morphine, codeine, thebaine Cinchona bark Quinine Vinca rosea periwinkle plant Vinca alkaloids Podophyllum peltatum the mayapple
    [Show full text]
  • On the Approximation of the Laws of the Member States Relating to Cosmetic Products (76/768/EEC )
    27 . 9 . 76 Official Journal of the European Communities No L 262/169 COUNCIL DIRECTIVE of 27 July 1976 on the approximation of the laws of the Member States relating to cosmetic products (76/768/EEC ) THE COUNCIL OF THE EUROPEAN COMMUNITIES, regards the composition, labelling and packaging of cosmetic products ; Having regard to the Treaty establishing the Euro­ pean Economic Community, and in particular Whereas this Directive relates only to cosmetic prod­ Article 100 thereof, ucts and not to pharmaceutical specialities and medicinal products ; whereas for this purpose it is necessary to define the scope of the Directive by Having regard to the proposal from the Commission, delimiting the field of cosmetics from that of phar­ maceuticals ; whereas this delimitation follows in particular from the detailed definition of cosmetic Having regard to the opinion of the European Parlia­ products, which refers both to their areas of appli­ ment ( 1 ), cation and to the purposes of their use; whereas this Directive is not applicable to the products that fall Having regard to the opinion of the Economic and under the definition of cosmetic product but are Social Committee (2 ), exclusively intended to protect from disease; whereas, moreover, it is advisable to specify that certain prod­ ucts come under this definition, whilst products Whereas the provisions laid down by law, regulation containing substances or preparations intended to be or administrative action in force in the Member ingested, inhaled, injected or implanted in the human States
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • List of Ingredients Prohibited in Cosmetic Products This Rule Has Been Translated Into English According to the Original Chinese Version
    List of Ingredients Prohibited in Cosmetic Products This rule has been translated into English according to the original Chinese version. If there is any inconsistency or ambiguity between these two versions, the Chinese version shall prevail. No. Chemical name CAS No. Mercury and its compounds (with the exception of the substance listed in the “List of Preservatives in Cosmetic Products”) 1 7439-97-6 Due to the raw material or other technically unavoidable reasons, the trace amounts of Mercury shall not exceed 1 ppm. 103-16-2/ 2 4-Benzyloxyphenol and 4-ethoxyphenol 622-62-8 3 Bithionol 97-18-7 4 Pilocarpine and its salts 92-13-7 5 Halogeno-salicylanilide - 10043-35-3/ 6 Boric acid 11113-50-1 7 Sodium perborate 7632-04-4 Sodium borate 8 1330-43-4 except for sodium borate used to emulsify beeswax or bleached beeswax, which content should not exceed 0.76% 9 Chlorofluorocarbons - 10 3'-Ethyl-5',6',7',8'-tetrahydro-5',5',8',8'-tetramethyl-2'- acetonaphthone or 7-acetyl-6-ethyl-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphtalen (AETT; Versalide) 88-29-9 11 Cells, tissues or products of human origin - Hydroxy-8-quinoline and its sulphate 148-24-3/ 12 For use as stabilizer of hydrogen peroxide in hair dyes and perming products, the content should not exceed 0.03% (calc. as base) 134-31-6 13 Dichloromethane 75-09-2 14 4-tert-Butyl-3-methoxy-2,6-dinitrotoluene (Musk ambrette) 83-66-9 15 6-Methylcoumarin (Non-medical toothpaste and mouthwash are otherwise specified by law) 92-48-8 16 Vinyl chloride monomer 75-01-4 17 2,2'-Dihydroxy-3,3',5,5',6,6'-hexachlorodiphenylmethane (Hexachlorophene (INN)) 70-30-4 18 Tretinoin (INN) (retinoic acid and its salts) 302-79-4 19 4-Amino-2-nitrophenol 119-34-6 20 Antimony and its compounds 7440-36-0 Arsenic and its compounds 21 7440-38-2 Due to the raw material or other technically unavoidable reasons, the trace amounts of Arsenic shall not exceed 3 ppm.
    [Show full text]
  • Codeine and Its Alternates for Pain and Cough Relief
    Codeine and its Alternates for Pain and Cough Relief 3. The Antitussive Action of Codeine-Mechanism, Methodology and Evaluation This report-the third of a series on codeine and its alternates for pain and cough relief-presents a detailed review of the physiology and pathophysiology of cough, the methods for the experimental and clinical measurement of the antitussive action of drugs, possible mechanisms of action of antitussive agents, and includes a compilation of experi­ mental results and clinical experience with codeine as an antitussive. CONTENTS INTRODUCTION 127 PHARMACOLOGICAL COMPONENTS OF THE ANTITUSSIVE EFFECT • MECHANISM AND SIGNIFICANCE OF COUGH 128 136 ANTITUSSIVE ACTION OF CODEINE 143 METHODS FOR THE STUDY OF ANTITUSSIVE RESUME 153 ACTION 130 REFERENCES 154 INTRODUCTION of codeine has increased greatly in recent years (see Part 4) but the popularity of codeine continues and Codeine was first used as a therapeutic antitussive its annual consumption remains at a high level, paral­ agent soon after its separation as an alkaloidal entity leling the high frequency of need for relief of cough (Martin, 1834) and some of the earliest accounts of as a symptom, especially chronic cough. Bickerman dosage and of the circumstances of its use are sum­ (1960) estimated, not so long ago, that 13% of the marized by K.rueger, Eddy & Sumwalt (1943). population of the United States of America was more Codeine has indeed dominated the picture with than 65 years old and that there were not less than respect to the symptomatic management of cough, 1 300 000 chronic coughers. Watt (1958) estimated with only minor variations, and this situation has that in the United Kingdom of Great Britain and been influenced little by the intro,duction of sub­ Northern Ireland 10% of all prescriptions were for stances claimed to be superior in effectiveness and cough relief.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0120756A1 Gant Et Al
    US 20100120756A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0120756A1 Gant et al. (43) Pub. Date: May 13, 2010 (54) PHENOTHIAZINE MODULATORS OF H1 A6IP 25/22 (2006.01) RECEPTORS A6IP 9/10 (2006.01) A6IP35/00 (2006.01) (75) Inventors: Thomas G. Gant, Carlsbad, CA (52) U.S. Cl. ........................................ 514/226.2:544/41 (US); Sepehr Sarshar, Cardiff by the Sea, CA (US) (57) ABSTRACT Correspondence Address: The present invention relates to new phenothiazine modula Global Patent Group, LLC tors of H1 receptors, pharmaceutical compositions thereof, 10411 Clayton Road, Suite 304 and methods of use thereof. St Louis, MO 63131 (US) (73) Assignee: AUSPEX Formula I PHARMACEUTICALS, INC., Vista, CA (US) (21) Appl. No.: 12/561,572 (22) Filed: Sep. 17, 2009 Related U.S. Application Data (60) Provisional application No. 61/097.593, filed on Sep. R2 N R7 17, 2008. Publication Classification R S R6 (51) Int. Cl. R4 Rs A6 IK3I/545 (2006.01) CO7D 279/24 (2006.01) US 2010/0120756 A1 May 13, 2010 PHENOTHAZINE MODULATORS OF H1 occurrence and/or severity of these side effects. Metabolism RECEPTORS of promethazine, occurs in part through polymorphically expressed enzymes, exacerbating interpatient variability. For example, patients who were genetically deficient in CYP2D6 0001. This application claims the benefit of priority of (poor metabolizer phenotype), could potentially have an U.S. provisional application No. 61/097.593, filed Sep. 17, exaggerated response and/or serious and toxic effects at 2008, the disclosure of which is hereby incorporated by ref therapeutic doses. erence as if written herein in its entirety.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]